SK286313B6 - Solid oral galenical form with prolonged release of molsidomine - Google Patents

Solid oral galenical form with prolonged release of molsidomine Download PDF

Info

Publication number
SK286313B6
SK286313B6 SK1220-2002A SK12202002A SK286313B6 SK 286313 B6 SK286313 B6 SK 286313B6 SK 12202002 A SK12202002 A SK 12202002A SK 286313 B6 SK286313 B6 SK 286313B6
Authority
SK
Slovakia
Prior art keywords
molsidomine
hours
release
form according
galenic
Prior art date
Application number
SK1220-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK12202002A3 (sk
Inventor
Jozsef-Michel Geczy
Original Assignee
Therabel Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Ltd filed Critical Therabel Pharmaceuticals Ltd
Publication of SK12202002A3 publication Critical patent/SK12202002A3/sk
Publication of SK286313B6 publication Critical patent/SK286313B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK1220-2002A 2000-02-24 2001-02-22 Solid oral galenical form with prolonged release of molsidomine SK286313B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002307A FR2805462B1 (fr) 2000-02-24 2000-02-24 Nouvelle forme galenique orale a liberation prolongee de la molsidomine
PCT/EP2001/002055 WO2001062256A1 (fr) 2000-02-24 2001-02-22 Nouvelle forme galenique orale a liberation prolongee de la molsidomine

Publications (2)

Publication Number Publication Date
SK12202002A3 SK12202002A3 (sk) 2002-12-03
SK286313B6 true SK286313B6 (en) 2008-07-07

Family

ID=8847342

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1220-2002A SK286313B6 (en) 2000-02-24 2001-02-22 Solid oral galenical form with prolonged release of molsidomine

Country Status (36)

Country Link
US (1) US7767227B2 (hu)
EP (1) EP1265614B1 (hu)
JP (1) JP4945043B2 (hu)
KR (1) KR100814191B1 (hu)
CN (1) CN100396284C (hu)
AT (1) ATE296632T1 (hu)
AU (2) AU4065301A (hu)
BE (1) BE1013487A3 (hu)
BG (1) BG66111B1 (hu)
BR (1) BRPI0108041B8 (hu)
CA (1) CA2400886C (hu)
CZ (1) CZ301993B6 (hu)
DE (1) DE60111196T2 (hu)
DZ (1) DZ3273A1 (hu)
EE (1) EE05098B1 (hu)
ES (1) ES2241803T3 (hu)
FR (1) FR2805462B1 (hu)
HK (1) HK1050138B (hu)
HR (1) HRP20020692B1 (hu)
HU (1) HU229799B1 (hu)
IL (2) IL151205A0 (hu)
IS (1) IS2446B (hu)
MA (1) MA25576A1 (hu)
MD (1) MD3119C2 (hu)
MX (1) MXPA02008262A (hu)
NO (1) NO329495B1 (hu)
NZ (1) NZ520691A (hu)
OA (1) OA12183A (hu)
PL (1) PL201631B1 (hu)
PT (1) PT1265614E (hu)
RS (1) RS50291B (hu)
RU (1) RU2263506C2 (hu)
SK (1) SK286313B6 (hu)
UA (1) UA73972C2 (hu)
WO (1) WO2001062256A1 (hu)
ZA (1) ZA200206042B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US7803402B2 (en) * 2002-07-06 2010-09-28 Sanjeev Khandelwal Pharmaceutical preparations
FR2868314B1 (fr) * 2004-04-05 2008-10-24 Therabel Pharmaceuticals Ltd Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
EP2468269A1 (en) 2010-11-26 2012-06-27 Universitätsklinikum Münster Nitric oxide donors in therapy of nitric oxide deficiency-induced disturbances of cerebral microcirculation
BE1028879B1 (fr) 2020-12-11 2022-07-12 Europharmaceuticals Comprimé à libération prolongée de la molsidomine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3522191A1 (de) * 1985-06-21 1987-01-15 Cassella Ag Photostabilisierung von sydnoniminen
CN1006522B (zh) * 1986-04-30 1990-01-24 田道制药有限公司 缓放性制剂的制备方法
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU211648A9 (en) * 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
ATE185273T1 (de) * 1993-05-11 1999-10-15 Hoechst Ag Galenische zubereitungen von molsidomin
JPH09503997A (ja) * 1993-07-08 1997-04-22 シグナス，インコーポレイテッド モノリシックなマトリックス経皮送達システム
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
HU218280B (en) * 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
DE4443105C2 (de) * 1994-12-03 1997-03-13 Hoechst Ag Verfahren zur Herstellung Molsidomin-haltiger Tabletten
JPH09114680A (ja) * 1995-10-19 1997-05-02 Fuji Xerox Co Ltd シーケンス制御装置
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
AU9496798A (en) * 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine

Also Published As

Publication number Publication date
JP4945043B2 (ja) 2012-06-06
ES2241803T3 (es) 2005-11-01
AU2001240653B2 (en) 2005-05-26
HRP20020692B1 (en) 2011-10-31
ATE296632T1 (de) 2005-06-15
NO329495B1 (no) 2010-11-01
FR2805462B1 (fr) 2003-08-15
IL151205A0 (en) 2003-04-10
UA73972C2 (en) 2005-10-17
MA25576A1 (fr) 2002-10-01
SK12202002A3 (sk) 2002-12-03
HRP20020692A2 (en) 2004-02-29
MD20020212A (en) 2002-12-31
IS6504A (is) 2002-08-14
ZA200206042B (en) 2003-07-29
AU4065301A (en) 2001-09-03
RU2002121503A (ru) 2004-03-20
US7767227B2 (en) 2010-08-03
NO20024043D0 (no) 2002-08-23
HUP0300607A2 (hu) 2003-08-28
HU229799B1 (en) 2014-07-28
RS50291B (sr) 2009-09-08
CA2400886C (fr) 2011-04-19
EE05098B1 (et) 2008-12-15
HK1050138B (zh) 2005-07-29
OA12183A (fr) 2006-05-09
CZ301993B6 (cs) 2010-09-01
BG107027A (bg) 2003-04-30
KR20020081323A (ko) 2002-10-26
MXPA02008262A (es) 2004-04-05
CA2400886A1 (fr) 2001-08-30
EP1265614B1 (fr) 2005-06-01
JP2003523981A (ja) 2003-08-12
AU2001240653B9 (en) 2005-10-27
YU62202A (sh) 2006-01-16
BR0108041B1 (pt) 2013-06-18
CN100396284C (zh) 2008-06-25
NZ520691A (en) 2004-07-30
CN1419451A (zh) 2003-05-21
NO20024043L (no) 2002-08-23
PT1265614E (pt) 2005-10-31
BRPI0108041B8 (pt) 2021-05-25
IS2446B (is) 2008-11-15
EE200200472A (et) 2003-12-15
MD3119B2 (en) 2006-08-31
BG66111B1 (bg) 2011-05-31
BE1013487A3 (fr) 2002-02-05
HK1050138A1 (en) 2003-06-13
PL201631B1 (pl) 2009-04-30
EP1265614A1 (fr) 2002-12-18
DE60111196T2 (de) 2006-05-11
BR0108041A (pt) 2002-10-29
FR2805462A1 (fr) 2001-08-31
WO2001062256A1 (fr) 2001-08-30
RU2263506C2 (ru) 2005-11-10
DZ3273A1 (fr) 2001-08-30
MD3119C2 (ro) 2007-04-30
US20030045522A1 (en) 2003-03-06
KR100814191B1 (ko) 2008-03-17
PL357550A1 (en) 2004-07-26
DE60111196D1 (de) 2005-07-07
HUP0300607A3 (en) 2006-02-28
IL151205A (en) 2011-01-31

Similar Documents

Publication Publication Date Title
KR101234940B1 (ko) 안정한 서방출형의 경구 투여용 조성물
ES2330873T3 (es) Composicion para dosificacion oral de liberacion prolongada.
AU2001260212B2 (en) Composition
US20160030399A1 (en) Method of reducing somnolence in patients treated with tizanidine
SK55896A3 (en) Pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
CA2451519C (en) Tablet comprising cetirizine and pseudoephedrine
HU202753B (en) Process for producing retard pharmaceutical compositions containing cetotiphene
SK286313B6 (en) Solid oral galenical form with prolonged release of molsidomine
Frishman A new extended‐release formulation of diltiazem HCl for the treatment of mild‐to‐moderate hypertension
JPH0448776B2 (hu)
KR101199654B1 (ko) 안정한 서방출형의 경구 투여용 조성물
MXPA97006492A (en) Use of isosorb 5-mononitrate

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20210222